Issue link: http://osercommunicationsgroup.uberflip.com/i/709452
C h a i n D r u g s t o r e D a i l y S u n d a y, A u g u s t 7 , 2 0 1 6 1 2 CARE-DRIVEN VALUE-ADDED PHARMACY ACCREDITATION The Compliance Team's (TCT) pharma- cy accreditation is the first accreditation model that is operations-based and care- driven, built upon existing day-to-day pharmacy routines while incorporating simplified measures to account for today's star-ratings payment and regula- tory realities. There's also a hands-on aspect to The Compliance Team's accreditation process that isn't found in other national- ly recognized accreditation programs. Each new participating pharmacy is assigned a TCT Advisor who acts as a mentor throughout the implementation process, conducting a series of webinars and teleconferences dealing with every aspect of a pharmacy's daily business and patient care practices. Process simplification is the key. The Compliance Team's industry-leading Safety-Honesty-Caring ® quality stan- dards serve as plain language templates for setting in place an operations-based measured improvement program that helps pharmacies streamline their patient care practices and improve overall opera- tional efficiencies with- out disrupting their exist- ing everyday work envi- ronments to do so. In addition, its Medicare-approved DMEPOS accreditation is included in every TCT Community Pharmacy pro- gram. Also featured are tracks for Infusion, Sterile and Non-sterile Compounding, Specialty Drugs, Long Term Care and an In-store Clinic accreditation based on its Part A Medicare-approved program for Rural Health Clinics. Adding to all that, the company gives participating pharmacies access to its national Patient Quality Measurement© satis- faction reporting and benchmarking data- base service, the industry's oldest and largest, and more than 200 accreditation-related document tem- plates. Given all that, it is no wonder that The Compliance Team's Exemplary Provider ® program is considered the very definition of care-driven value-added pharmacy accreditation. Visit The Compliance Team at booth #2323. For more information, go to www.thecomplianceteam.org or call 215.654.9110. TAGI PHARMA ANNOUNCES LAUNCH OF BENZONATATE CAPSULES, USP 200MG AND METFORMIN ER TABLETS, USP 500MG, 750MG TAGI Pharma, Inc., a specialty pharma- ceutical company and subsidiary of Precision Dose, Inc., launched the FDA approved Benzonatate Capsules, USP 200mg available in the United States and its territories, possessions and protec- torates. Benzonatate Capsules, USP 200mg is a non-narcotic oral antitussive. Visit www.tagipharma.com to view the full prescribing information, which includes indications for usage and additional important safety information. July 2016 – TAGI Pharma, Inc. is launching the FDA approved Metformin ER Tablets, USP 500mg and 750mg in 100 count and 500 count bottles, avail- able in the United States and its territo- ries, possessions and protectorates. Metformin ER Tablets, USP 500mg and 750mg is a hypo- glycemic agent, a non- insulin, biguanide antidi- abetic. Visit www.tagipharma.com to view the full prescribing information which includes indications for usage and additional important safety information. About TAGI Pharma With a robust pipeline and product mix, TAGI Pharma is providing market oppor- tunities in both Retail and Institutional segments. TAGI's portfolio maintains product emphasis on tablets and capsules while encompassing liquids, powders, creams and emollient foams. TAGI's strength is derived from its understand- ing of the market, product quality and high service levels. Its current and still expanding product portfolio consists of 10 product families with 20 SKUs, including the sole source generic Alendronate Sodium Oral Solution. Visit TAGI Pharma at booth #2322. For more information, go to www.tagi pharma.com or call 855.225.8244, contact Kenneth Harrington, Vice President of National Sales and Marketing at kharrington @tagipharma.com or 815.624.7685 ext. 203, or contact Thomas Anderson, Executive President (Business Development Inquiries) at tanderson@tagipharma.com or 410.241.2165. CLINICAL EXPANSION DRIVES PHARMACY PROFITS Recent years have brought unprecedent- ed challenges to the practice of pharma- cy. Today, pharmacies are seeing lower profit-per-script from mushrooming generic use and lower margins from the proliferation of closed and limited net- works. In anticipation of these and other challenges, MarkeTouch Media has invested heavily in developing truly innovative technology solutions, expand- ing its platform from custom patient communications to become a full-service clinical provider. MarkeTouch Media's Clinical Intervention Suite is a robust, fully cus- tomizable engine that empowers phar- macists to have targeted clinical con- versations with patients while easing workflow burden on pharmacy staff. It includes multiple modules that enable client pharmacies to target and manage specific patient populations while max- imizing contract incentives and mini- mizing penalties. MarkeTouch Media first analyzes the entire patient popula- tion, calculates PDC and a proprietary adherence score, notes whether immu- nizations or other services are needed, and then provides the list of clients to target for interventions, helping the pharmacy meet its contract objectives. Solutions targeted at DIR incentives focus on PDC scores across the entire Payor by drug class, while specialty pharmacy modules focus on patient assessments and data at intervals spe- cific to each drug or dis- ease state. MarkeTouch's staff applies industry- leading expertise and best practices to effectively deploy clinical programs designed to meet clients' goals and met- rics. In addition, MarkeTouch's capabili- ties and scale (a network of more than 14,000 retail pharmacies) enable it to readily run customized pilots for its clients, who can see for themselves the efficacy of the technology in driving down healthcare costs. For instance, MarkeTouch Adherence Interventions were able to increase PDC scores of tar- geted drug classes by more than 30 per- cent in 180 days by identifying and addressing barriers to adherence in retail pharmacy environments. MarkeTouch Media's RxTouch SM Pharmacist Connect is a fully hosted solution that streamlines pharmacy operations and allows each patient to choose preferred communication channels for pharmacy interaction. By employing the patients' channel preferences, the pharmacy can achieve greater adherence and persisten- cy to the prescribed regimen. Each client has the ability to select campaigns that ensure targeted patients make a positive impact on quality and operational met- rics, resulting in a maximized ROI, reduced overall healthcare costs, and ulti- mately, better clinical outcomes for patients. Visit MarkeTouch Media at booth #421. For more information, go to www.rxtouch.com. MAYNE PHARMA LAUNCHES FIRST GENERIC TIKOSYN WITHOUT REMS Dofetilide capsules, the first generic alternatives to Tikosyn ® , an anti-arrhyth- mic agent, are now available from Mayne Pharma. The U.S. Food and Drug Administration (FDA) recently awarded Mayne Pharma 180 days of market exclu- sivity for its new generic alternatives to Tikosyn. The company is selling the prod- uct in 125 mcg (0.125 mg), 250 mcg (0.25 mg) and 500 mcg (0.5 mg) doses. The timing of Mayne Pharma's mar- ket approval for dofetilide capsules coin- cided with the FDA withdrawing the Tikosyn Risk Evaluation and Mitigation Strategies (REMS) program, which limit- ed the drug's availability and dispensa- tion to certified prescribers, pharmacies and wholesalers. The removal of the drug's REMS program means Mayne Pharma's dofetilide capsules are broadly available to pharmacies nationwide, improving availability for current and new patients. "Mayne Pharma has a long history of developing high-quality generic products that offer patients affordable options and improved access to medications that enhance their lives," said Stefan Cross, President of Mayne Pharma USA. "The launch of Mayne Pharma's dofetilide capsules with 180 days of market exclusivity repre- sents a large step forward in our com- pany's growth – underscoring our commitment through our staff and investments to bring complex gener- ic alternatives to the marketplace." Dofetilide capsules are a generic version of Pfizer's branded Tikosyn capsules, an anti-arrhythmic agent used to prevent irregular heartbeats such as atrial fibrillation and atrial flutter. According to IMS Health, annual sales of Tikosyn in the United States were approximately $180 million in 2015 and growing at the rate of seven percent annually. Mayne Pharma has an agreement with its long-time part- ner, Johnson Matthey Inc., which supplies the active pharmaceutical ingredient (API), to share equally the profits from the sale of this product. Tikosyn is a registered trademark of Pfizer Inc. Currently, Mayne Pharma has more than 35 generic and branded drug products in development for the market within the United States, including 12 drug applications pending at the FDA. Connect with Mayne Pharma team members to learn more about dofetilide capsules. Visit Mayne Pharma at booth #1513.